Advertisement
UK markets close in 4 hours 59 minutes
  • FTSE 100

    8,357.13
    +43.46 (+0.52%)
     
  • FTSE 250

    20,426.29
    +13.21 (+0.06%)
     
  • AIM

    777.63
    +1.21 (+0.16%)
     
  • GBP/EUR

    1.1615
    -0.0009 (-0.08%)
     
  • GBP/USD

    1.2491
    -0.0019 (-0.15%)
     
  • Bitcoin GBP

    49,995.46
    -1,115.63 (-2.18%)
     
  • CMC Crypto 200

    1,290.88
    -3.79 (-0.29%)
     
  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     
  • DOW

    38,884.26
    +31.99 (+0.08%)
     
  • CRUDE OIL

    77.58
    -0.80 (-1.02%)
     
  • GOLD FUTURES

    2,322.00
    -2.20 (-0.09%)
     
  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     
  • HANG SENG

    18,313.86
    -165.51 (-0.90%)
     
  • DAX

    18,518.12
    +88.07 (+0.48%)
     
  • CAC 40

    8,144.81
    +69.13 (+0.86%)
     

How AbbVie’s Humira Performed in 4Q17 and 2017

How AbbVie’s Humira Performed in 4Q17 and 2017

AbbVie’s (ABBV) Humira generated revenue of $4.9 billion in 4Q17 and $4.3 billion in 4Q16, reflecting ~14% growth YoY (year-over-year) and ~4% growth quarter-over-quarter. In 4Q17, in US and international markets, Humira reported revenue of $3.3 billion and $1.6 billion, respectively, marking ~15.1% and ~11.7% growth YoY.